Brookstone Capital Management lessened its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating) by 0.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,135 shares of the medical instruments supplier's stock after selling 50 shares during the quarter. Brookstone Capital Management's holdings in West Pharmaceutical Services were worth $2,272,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in WST. Allworth Financial LP increased its position in shares of West Pharmaceutical Services by 140.0% in the first quarter. Allworth Financial LP now owns 72 shares of the medical instruments supplier's stock valued at $30,000 after buying an additional 42 shares in the last quarter. Addison Advisors LLC grew its stake in West Pharmaceutical Services by 221.7% in the 1st quarter. Addison Advisors LLC now owns 74 shares of the medical instruments supplier's stock valued at $30,000 after acquiring an additional 51 shares during the period. Artemis Wealth Advisors LLC purchased a new stake in West Pharmaceutical Services in the 1st quarter worth $35,000. American National Bank raised its position in West Pharmaceutical Services by 55.6% during the first quarter. American National Bank now owns 98 shares of the medical instruments supplier's stock worth $40,000 after acquiring an additional 35 shares during the period. Finally, Dividend Assets Capital LLC purchased a new position in West Pharmaceutical Services during the fourth quarter valued at $51,000. Hedge funds and other institutional investors own 91.98% of the company's stock.

West Pharmaceutical Services Stock Down 2.3 %

WST stock opened at $263.69 on Wednesday. West Pharmaceutical Services, Inc. has a 52 week low of $261.31 and a 52 week high of $475.00. The company has a quick ratio of 2.41, a current ratio of 3.13 and a debt-to-equity ratio of 0.09. The firm has a 50-day simple moving average of $311.87 and a 200-day simple moving average of $329.79. The stock has a market capitalization of $19.53 billion, a P/E ratio of 29.27, a P/E/G ratio of 1.09 and a beta of 1.18.

Insider Buying and Selling

In other West Pharmaceutical Services news, insider Silji Abraham sold 5,374 shares of West Pharmaceutical Services stock in a transaction on Monday, August 1st. The shares were sold at an average price of $343.93, for a total transaction of $1,848,279.82. Following the sale, the insider now owns 3,201 shares of the company's stock, valued at approximately $1,100,919.93. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.60% of the stock is owned by company insiders.

About West Pharmaceutical Services

(Get Rating)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Further Reading

• Get a free copy of the StockNews.com research report on West Pharmaceutical Services (WST)
• 3 Airline Stocks Stuck in a Holding Pattern
• Roku Stock is Down but Not Out
• If You're Hungry for Value, Take a Bite on Ruth's Hospitality Grp
• Is Ford Rolling To A Rebound After Its Q3 Warning
• Has AMD stock stock fallen too far?

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST – Get Rating).

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.